drugset / Trial / NCT02848079

TAS-OX for Refractory Metastatic Colon Cancer

NCT02848079

Phase 1/2 Completed 41 enrolled Yale University
NaSingle-groupOpen-labelTreatment

Summary

This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.

Timeline

Start
2016-10-31
Primary completion
2020-06-02
Completion
2020-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule Other
Subject TAS-102 Small molecule Oral

Indications